GO Capital Becomes Major Shareholder in ThromboGenics

LEUVEN, Belgium, March 27 /PRNewswire/ --

- GO Capital Acquires Shares From Biggar Limited, The Company's Largest Shareholder

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that Global Opportunities Capital Asset Management BV, also known as GO Capital, a Dutch-based asset manager, has acquired 1.2 million shares in the company, representing approximately 5.4% of its outstanding shares. The acquisition of this stake from Biggar Limited makes GO Capital one of ThromboGenics' major shareholders. As a result of this transaction, Biggar's holding in ThromboGenics is reduced to 33.5%.

The transaction, which was executed at nearly market price, was mediated by Kempen Securities.

Commenting on today's announcement, Prof. Desire Collen, CEO of ThromboGenics, said: "We are pleased that GO Capital, a highly regarded asset manager and experienced investor in the biotech space, has decided to acquire a significant position in ThromboGenics. This is an important vote of confidence in our product pipeline, our management team and our cutting edge science. We look forward to their long term support as we work to maximize the value of our late stage clinical pipeline, particularly microplasmin for the treatment of back of the eye diseases and certain vascular disorders."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics also has five other drug candidates in preclinical development with preclinical proof-of-principle demonstrated, including TB-402 (Anti-Factor VIII) and TB-403 (Anti-PlGF). The Company has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Ireland and the U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.